Innovent Biologics Inc. (1801.HK) announced first-quarter product revenue of over RMB 3.8 billion, a surge of more than 50 percent year-over-year, driven by newly reimbursed medicines.
The company did not provide a direct quote from management in the announcement.
The robust growth was primarily attributed to the rapid increase in sales volume after five of the company's tyrosine kinase inhibitors (TKIs) were included in China's National Reimbursement Drug List (NRDL). Core products, including Sintilimab (mazdutide injection), Xinbile (tolebrutinib injection), and Xinbimin (teprotumumab N01 injection), also showed outstanding performance. The company did not disclose net profit or earnings per share for the quarter.
The strong sales performance underscores Innovent's successful commercialization strategy and its ability to capitalize on the NRDL inclusion. The results position the company for continued growth as it invests in its late-stage pipeline.
Innovent is advancing three high-potential molecules into or near global multi-regional Phase III clinical trials: IBI363 (a PD-1/IL-2 bispecific antibody), IBI343 (a CLDN18.2 ADC), and IBI324 (a VEGF/ANG2 bispecific antibody). These assets represent significant future revenue opportunities.
The company also stated it will continue to invest in early-stage innovation to drive the global clinical development of its next-generation pipelines in oncology, cardiovascular and metabolic (CVM), autoimmune, and ophthalmology fields.
The strong first-quarter results signal that Innovent's strategy of expanding its product portfolio and securing reimbursement is paying off. Investors will be watching for the successful execution of its late-stage clinical trials as the next major catalyst for the company.
This article is for informational purposes only and does not constitute investment advice.
